Is Procter & Gamble Health Ltd (PGHL) a good quality company?

Past 10 year's financial track record analysis by Moneyworks4me indicates that Procter & Gamble Health Ltd is a good quality company .

Is Procter & Gamble Health Ltd (PGHL) undervalued or overvalued?

The key valuation ratios of Procter & Gamble Health Ltd's currently when compared to its past seem to suggest it is in the Somewhat overvalued zone .

What is Procter & Gamble Health Ltd (PGHL) share price return in the past 10 years?

Procter & Gamble Health Ltd share price has appreciated 22.6% annually (CAGR) over the past ten years.

Is Procter & Gamble Health Ltd (PGHL) a good buy now?

The Price Trend analysis by MoneyWorks4Me indicates it is Semi Strong which suggest that the price of Procter & Gamble Health Ltd is likely to Rise-somewhat in the short term. However, please check the rating on Quality and Valuation before investing.

What is the share price of Procter & Gamble Health Ltd (PGHL)?

Company share prices are keep on changing according to the market conditions. The current trading price of Procter & Gamble Health Ltd (PGHL) on 17-Apr-2026 16:59:59 at 16:59 is 5021.30.

What is the P/E ratio of Procter & Gamble Health?

The latest standalone P/E ratio of Procter & Gamble Health as of 17-Apr-2026 is 28.40.

What is the P/B ratio of Procter & Gamble Health Ltd (PGHL)?

The latest standalone P/B ratio of Procter & Gamble Health Ltd (PGHL) as of 17-Apr-2026 is 11.95.

What is the 52-week high and low of Procter & Gamble Health Ltd (PGHL)?

The 52-week high of Procter & Gamble Health Ltd (PGHL) is Rs. 6700.00 and the 52-week low is Rs. 4699.70.

Procter & Gamble Health Ltd (PGHL) Share Analysis – Quality, Pipeline & Valuation Zone & DeciZen Rating

Name: Procter & Gamble Health Ltd (PGHL)
Brand: Procter & Gamble Health

Procter & Gamble Health Ltd (PGHL) Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating

Procter & Gamble Health Ltd (PGHL)

BSE: 500126 NSE: PGHL

Key Metrics

Market Cap

₹8,335 Cr.

P/E Ratio

28.40

Price to Book (P/B)

11.95

Price to Sales (P/S)

6.18

EV/EBITDA

19.24

Return on Capital Employed (ROCE)

58.05%

Current Price

₹5,021.3

Return on Equity (ROE)

44.15%

Return on Assets (ROA)

30.85%

Operating Profit Margin

34.1%

Net Profit Margin

25.09%

Gross Profit Margin

31.9%

Book Value per Share

₹420.1

Sales Growth (YoY)

8.19%

Sales Growth (3 Years)

0.43%

Operating Profit Growth (1 Year)

4.05%

Operating Profit Growth (3 Years)

5.95%

Net Profit Growth (1 Year)

16.63%

52-Week Low / High

₹4,700 / 6,700

Net Profit Growth (3 Years)

6.78%

Dividend Yield

2.43%

Promoter Holding

51.82%

Pledged shares (%)
of Promoter's holding (%)

0.00%

Check Before You Invest

Q.1 Revenue growth of Procter & Gamble Health Ltd?

Procter & Gamble Health Ltd revenue growth is 8.2% for FY-2025 , which is above its 5 year CAGR of 4.3% , indicating faster growth.

Q.1 Promoter shareholding and pledge status of Procter & Gamble Health Ltd?

Promoters hold 51.82% of the Procter & Gamble Health Ltd, with 0.00% of their stake pledged, indicating no pledge risk.

Q.1 Revenue growth of Procter & Gamble Health Ltd vs industry peers?

Procter & Gamble Health Ltd revenue CAGR is 4.31% , compared to the industry median CAGR of 5.54% , indicating slower growth and losing its market share.

Q.1 Which industry/sub-sector does Procter & Gamble Health Ltd belong to?

Procter & Gamble Health Ltd belongs to the Healthcare sector, operating specifically within the Pharmaceuticals & Drugs segment.

Q.1 Stock return of Procter & Gamble Health Ltd over the last decade?

Over the last 9 year(s), the stock has delivered a CAGR of 22.7% based on the current price.

DeciZen - make an informed investing decision on Procter&Gamble Healt

Based on:

Data

Overall Rating ⓘ
Login to view analysis.

1. Quality

2. Valuation

3. Price Trend

Procter & Gamble Health stock performance

Key Ratios

Is Procter & Gamble Health Ltd an attractive stock to invest in?

10 Year X-Ray : Login to view analysis.

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Value Creation ⓘ

Value Creation Index Colour Code Guide ⓘ

	Dec'16	Dec'17	Dec'18	Jun'20	Jun'21	Jun'22	Jun'23	Mar'24	Jun'24	Mar'25	TTM
ROCE % ⓘ	18.4%	14.2%	13.9%	29%	29.1%	38.5%	46.1%	0%	42.5%	58.1%	-
Value Creation Index ⓘ	0.3	0.0	0.0	1.2	1.2	1.9	2.4	NA	2.2	3.3	-
Growth Parameters ⓘ Growth Parameters Colour Code Guide ⓘ
Sales ⓘ	993	698	849	904	1,009	1,114	1,230	1,151	1,151	1,246	1,349
Sales YoY Gr.	-	-29.7%	21.6%	6.5%	11.6%	10.5%	10.3%	-6.4%	0%	8.2%	-
Adj EPS ⓘ	46.6	28.8	58.1	102.2	107.1	116.5	137.8	129.7	129.7	188.5	176.8
YoY Gr.	-	-38.3%	102.1%	75.9%	4.8%	8.8%	18.3%	-5.9%	0%	45.3%	-
BVPS (₹) ⓘ	399.9	441.7	927.8	363.2	421.6	367	447.6	319.1	319.1	427.4	420.1
Adj Net Profit ⓘ	77.4	47.8	96.5	170	178	193	229	215	215	313	294
Cash Flow from Ops. ⓘ	107	53.7	-130	157	247	170	236	228	228	225	-
Debt/CF from Ops. ⓘ	0	0	0	0	0	0	0	0	0	0	-

CAGR ⓘ

CAGR Colour Code Guide ⓘ

	9 Years	5 Years	3 Years	1 Years
Sales ⓘ	2.6%	4.3%	0.4%	8.2%
Adj EPS ⓘ	16.8%	12%	11%	45.3%
BVPSⓘ	0.7%	0.3%	-1.5%	33.9%
Share Price	22.6%	-4.6%	1.8%	-4%

Key Financial Parameters ⓘ

Performance Ratio Colour Code Guide ⓘ

	Dec'16	Dec'17	Dec'18	Jun'20	Jun'21	Jun'22	Jun'23	Mar'24	Jun'24	Mar'25	TTM
Return on Equity % ⓘ	12.3	6.8	8.5	20.8	22.1	29.3	33.5	33.4	33.4	43.6	41.7
Op. Profit Mgn % ⓘ	11.7	10.1	17	23.4	24.5	24.1	26.4	26.6	26.6	34.1	29.8
Net Profit Mgn % ⓘ	7.8	6.8	11.4	18.8	17.6	17.4	18.6	18.7	18.7	25.1	21.8
Debt to Equity ⓘ	0	0	0	0	0	0	0	0	0	0	-
Working Cap Days ⓘ	367	503	486	346	491	438	423	290	290	146	82
Cash Conv. Cycle ⓘ	66	88	49	12	-3	-22	-31	-33	-33	-36	51

Recent Performance Summary

Latest Financials

	Standalone	Consolidated
TTM EPS (₹)	176.8	-
TTM Sales (₹ Cr.)	1,349	-
BVPS (₹) ⓘ	420.1	-
Reserves (₹ Cr.) ⓘ	681	-
P/BV ⓘ	11.95	-
PE ⓘ	28.40	-

From the Market
52 Week Low / High (₹)	4699.70 / 6700.00
All Time Low / High (₹)	114.00 / 7499.95
Market Cap (₹ Cr.)	8,335
Equity (₹ Cr.)	16.6
Face Value (₹)	10
Industry PE ⓘ	42.1

Management X-Ray

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged ^*

0.00

* Pledged shares as % of Promoter's holding (%)

Valuation of Procter&Gamble Healt - Standalone Basis

YTD 1Y 3Y 5Y 10Y Max

Analyst's Notes

No data found!

Key Ratios

Adj EPS (Rs.)

Sales (Cr.)

ROE (%)

ROCE (%)

Profit And Loss

(All Figures are in Crores.)

PARTICULARS	Dec'15	Dec'16	Dec'17	Dec'18	Jun'20	Jun'21	Jun'22	Jun'23	Jun'24	Mar'25
Sales	940	993	698	849	1,356	1,009	1,114	1,230	1,151	934
Operating Expenses ⓘ +	856	877	628	705	1,042	763	847	905	845	616
Manufacturing Costs	86	73	81	85	140	139	147	139	122	87
Material Costs	437	412	237	269	431	312	340	362	331	263
Employee Cost	123	154	110	131	183	154	168	206	215	142
Other Costs ⓘ	210	238	200	220	287	158	193	198	178	124
Operating Profit ⓘ	83	116	71	144	314	246	268	325	306	318
Operating Profit Margin (%)	8.9%	11.6%	10.1%	17.0%	23.2%	24.4%	24.0%	26.4%	26.6%	34.1%
Other Income ⓘ +	23	24	30	28	70	18	13	18	16	10
Exceptional Items ⓘ	0	0	17	7	0	0	0	0	-20	0
Interest ⓘ	0	0	0	0	0	1	0	1	1	0
Depreciation ⓘ	23	25	19	21	29	30	27	28	27	17
Profit Before Tax ⓘ	83	115	99	158	355	233	253	314	273	312
Tax ⓘ	30	36	38	56	101	56	61	85	72	77
Profit After Tax	54	79	61	102	254	177	193	229	201	234
PAT Margin (%)	5.7%	8.0%	8.7%	12.0%	18.7%	17.5%	17.3%	18.7%	17.5%	25.1%
Adjusted EPS (₹)	32.3	47.7	36.8	61.3	153.1	106.5	116.0	138.2	121.1	141.2
Dividend Payout Ratio (%)	23%	23%	41%	718%	150%	122%	45%	69%	215%	89%

Balance Sheet

(All Figures are in Crores.)

PARTICULARS	Dec'15	Dec'16	Dec'17	Dec'18	Jun'20	Jun'21	Jun'22	Jun'23	Jun'24	Mar'25
Equity and Liabilities
Shareholders Fund +	592	664	733	1,540	904	700	609	743	530	532
Share Capital ⓘ	17	17	17	17	17	17	17	17	17	17
Reserves ⓘ	575	647	717	1,524	888	683	593	726	513	515
Debt +	0	0	0	0	0	0	0	0	0	0
Long Term Debt	0	0	0	0	0	0	0	0	0	0
Short Term Debt	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
Trade Payables	66	75	83	91	124	179	172	237	167	172
Others Liabilities ⓘ	868	624	699	951	1,084	1,099	1,157	1,253	64	55
Total Liabilities ⓘ	1,525	1,363	1,516	2,583	2,112	1,978	1,938	2,233	761	759
Fixed Assets
Net Fixed Assets ⓘ +	132	119	140	124	98	101	110	142	127	112
Gross Block	271	144	192	186	200	215	241	263	223	222
Accumulated Depreciation	140	25	51	61	102	114	131	121	97	110
CWIP ⓘ	7	30	9	17	21	39	41	32	6	11
Investments ⓘ	42	28	70	0	0	0	0	0	0	0
Inventories	167	164	158	113	134	118	115	135	109	109
Trade Receivables	127	107	123	66	95	60	83	116	85	145
Cash Equivalents	188	279	278	1,243	639	469	325	440	244	189
Others Assets ⓘ	863	636	738	1,018	1,124	1,191	1,264	1,368	189	193
Total Assets ⓘ	1,525	1,363	1,516	2,583	2,112	1,978	1,938	2,233	761	759

Cash Flow

(All Figures are in Crores.)

PARTICULARS	Dec'15	Dec'16	Dec'17	Dec'18	Jun'20	Jun'21	Jun'22	Jun'23	Jun'24	Mar'25
Cash Flow From Operating Activity ⓘ +	83	107	54	-130	235	247	170	236	228	169
PBT ⓘ	83	115	152	1,138	355	233	253	314	273	312
Adjustment ⓘ	16	15	8	-914	-12	41	27	41	52	12
Changes in Working Capital ⓘ	16	30	-47	-50	-6	41	-47	-30	-12	-74
Tax Paid ⓘ	-32	-53	-60	-304	-102	-68	-64	-90	-85	-81
Cash Flow From Investing Activity ⓘ +	-68	-75	-48	1,270	165	-32	-26	-22	-7	10
Capex	-45	-32	-10	-19	-23	-51	-38	-38	-22	-1
Net Investments	-39	-59	-57	214	124	0	0	0	0	0
Others ⓘ	16	16	20	1,075	64	19	12	16	15	10
Cash Flow From Financing Activity ⓘ +	-12	-15	-22	-30	-883	-387	-289	-98	-418	-235
Net Proceeds from Shares ⓘ	0	0	0	0	0	0	0	0	0	0
Net Proceeds from Borrowing ⓘ	0	0	0	0	0	0	0	0	0	0
Interest Paid ⓘ	0	0	0	0	0	0	0	0	0	0
Dividend Paid ⓘ	-10	-12	-18	-25	-733	-382	-284	-94	-415	-232
Others ⓘ	-2	-3	-4	-5	-150	-5	-5	-5	-3	-2
Net Cash Flow ⓘ	4	17	-16	1,109	-483	-172	-145	116	-197	-56

Finance Ratio

PARTICULARS	Dec'15	Dec'16	Dec'17	Dec'18	Jun'20	Jun'21	Jun'22	Jun'23	Jun'24	Mar'25
Ratios
ROE (%)	9.35	12.61	8.74	8.95	20.79	22.04	29.41	33.94	31.58	44.15
ROCE (%)	14.54	18.35	14.16	13.9	29.01	29.08	38.45	46.07	42.52	58.05
Asset Turnover Ratio	0.71	0.71	0.49	0.41	0.58	0.49	0.6	0.64	0.84	1.35
PAT to CFO Conversion(x)	1.54	1.35	0.89	-1.27	0.93	1.4	0.88	1.03	1.13	0.72
Working Capital Days
Receivable Days	43	41	59	41	22	28	22	27	29	41
Inventory Days	64	59	83	58	33	46	36	34	35	39
Payable Days	45	61	118	116	91	177	189	206	223	235

Top 5 Mutual Funds Holding

Last Visited Stocks

Announcements

Procter & Gamble Health Ltd FAQs

The current trading price of Procter&Gamble Healt on 17-Apr-2026 16:59 is ₹5,021.3.

Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 16-Apr-2026 the market cap of Procter&Gamble Healt stood at ₹8,335.1 Cr

The latest P/E ratio of Procter&Gamble Healt as of 16-Apr-2026 is 28.40.

The latest P/B ratio of Procter&Gamble Healt as of 16-Apr-2026 is 11.95.

The 52-week high of Procter&Gamble Healt is ₹6,700 and the 52-week low is ₹4,699.7.

The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Procter&Gamble Healt is ₹1,349 ( Cr.) .

About Procter & Gamble Health Ltd

Procter & Gamble Health Limited (formerly Merck Limited) was set up in India as one of Merck’s Asian subsidiaries in 1967. It was also the first Merck Group Company to go public in the year 1981. Till 2018, the Company was operating in all businesses included in the pharmaceuticals and chemicals businesses in the country.

On December 1st, 2018, P&G successfully completed the acquisition of Merck’s Consumer Health business further to approval of all relevant regulatory authorities and the fulfilment of other customary closing conditions. Procter & Gamble Overseas India B.V. now holds 51.81% of the share capital in Merck Limited, while the remaining 48.19% is traded on the Bombay Stock Exchange Ltd. and National Stock Exchange of India Ltd.

Currently, Procter & Gamble Health Limited (formerly Merck Limited) is one of India’s largest VMS Companies manufacturing and marketing over-the-counter products, vitamins, minerals, and supplements products for a healthy lifestyle and improved quality of life. Its trusted products are household names in India protecting and supporting millions of people at every stage of life. With a strong portfolio of brands backed by science and trusted by doctors, pharmacists and consumers, Procter & Gamble Health Limited combines the best of P&G and Legacy Merck’s Consumer Health capabilities and cultures. Together we are working towards leveraging our combined expertise to develop categories and brands that meet today’s needs and tomorrow’s opportunities.

Situated at Usgaon, Goa, the company’s Manufacturing Site has grown from a small Vitamin E producing unit to a big composite plant manufacturing pharma and chemical products.

Business area of the company

Till 2018, the Company was operating in all businesses included in the pharmaceuticals and chemicals businesses in the country. The company is one of India’s largest VMS Companies manufacturing and marketing over-the-counter products, vitamins, minerals, and supplements products for a healthy lifestyle and improved quality of life. Its trusted products are household names in India protecting and supporting millions of people at every stage of life.

Brands of the company

Neurobion
Evion
Seven Seas
Nasivion
Polybion
Livogen

Awards and achievements

2015-16: Merck Goa plant was awarded 1st prize in safety called “Gomant Sarvochcha Suraksha Puraskar”. This is consecutive 2nd time Merck Goa plant bagged 1st prize in safety. Prior to that Merck Goa plant bagged 2nd prize in safety “Gomant Uchcha Suraksha Puraskar” for two consecutive years.
2016-17: Consumer activation done for Neurobion under ‘True Heroes’ campaign won laurels at the Global level to receive President’s Award in 2017.
2017-18: Nasivion continued to be the Doctors’ trusted No. 1 Nasal Decongestant.
2019-20: Neurobion bagged three awards viz. Nicholas Hall Marketing Excellence Award; CIMS Trusted Brand of the Year; and ABP News Brand Excellence Award.

To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now

Build a Stress-Tested Portfolio.

Our Sapphire Advisory uses the ABC Concept to ensure you never have to panic during a market correction.

Core Stocks

STABILITY

Booster Stocks

GROWTH

Amplifier Stocks

ASYMMETRY

● Conflict-Free ● SEBI Registered ● 15Y+ Track Record

Name of the IA registered with SEBI:	The Alchemists Ark Pvt. Ltd.
Logo:
Trade/Brand Name of IA:	MoneyWorks4Me Investment Advisers
Brand Logo:
SEBI Registration Number:	INA000013323 Validity – May 16, 2019 – Perpetual
Registration:	Non-Individual
BSE Enlistment No:	1187
Address:	B-101, Signet Corner Building, Balewadi Phata, Baner, Pune, Maharashtra 411045
Compliance officer Details:	Name: Shrikant Jagtap Email: shrikant.jagtap@moneyworks4me.com Telephone: +919860359463 Address: Same as IA
Grievance Officer Details:	Name: Mukta Vaze Email: mukta.vaze@moneyworks4me.com Telephone: +91 98609 19463 Address: Same as IA
Principal Officer Details:	Name: Atharva Bhide Email: atharva.bhide@moneyworks4me.com Telephone: +91 91758 99463 Address: Same as IA
Standard Warning:	Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Disclaimer:	Registration granted by SEBI, enlistment with exchange and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

Procter & Gamble Health Ltd (PGHL) Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating

Procter&Gamble Healt Share Price